RIGL
Price:
$14.07
Market Cap:
$247.56M
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clini...[Read more]
Industry
Biotechnology
IPO Date
2000-11-29
Stock Exchange
NASDAQ
Ticker
RIGL
According to Rigel Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -18.27. This represents a change of -110.94% compared to the average of 167.00 of the last 4 quarters.
The mean historical PE Ratio of Rigel Pharmaceuticals, Inc. over the last ten years is -86.46. The current -18.27 PE Ratio has changed 2.01% with respect to the historical average. Over the past ten years (40 quarters), RIGL's PE Ratio was at its highest in in the December 2022 quarter at 896.53. The PE Ratio was at its lowest in in the June 2021 quarter at -133.61.
Average
-86.46
Median
-53.11
Minimum
-252.21
Maximum
-21.89
Discovering the peaks and valleys of Rigel Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 261.02%
Maximum Annual PE Ratio = -21.89
Minimum Annual Increase = -83.35%
Minimum Annual PE Ratio = -252.21
Year | PE Ratio | Change |
---|---|---|
2023 | -100.56 | 139.52% |
2022 | -41.98 | -83.35% |
2021 | -252.21 | 29.77% |
2020 | -194.35 | 261.02% |
2019 | -53.83 | 2.76% |
2018 | -52.39 | -16.64% |
2017 | -62.84 | 93.64% |
2016 | -32.46 | -37.67% |
2015 | -52.07 | 137.86% |
2014 | -21.89 | -21.66% |
The current PE Ratio of Rigel Pharmaceuticals, Inc. (RIGL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-131.59
5-year avg
-128.59
10-year avg
-86.46
Rigel Pharmaceuticals, Inc.’s PE Ratio is less than Fortress Biotech, Inc. (-0.70), less than Reviva Pharmaceuticals Holdings, Inc. (-1.05), greater than CTI BioPharma Corp. (-30.90), less than Ocuphire Pharma, Inc. (-2.14), less than Nabriva Therapeutics plc (-0.14), less than Eiger BioPharmaceuticals, Inc. (-0.03), less than Pieris Pharmaceuticals, Inc. (-0.93), less than Cidara Therapeutics, Inc. (-0.52), less than X4 Pharmaceuticals, Inc. (6.04), less than Mereo BioPharma Group plc (-16.88), less than Inozyme Pharma, Inc. (-3.09), less than Terns Pharmaceuticals, Inc. (-5.51), less than Leap Therapeutics, Inc. (-2.39), less than Zura Bio Limited (-10.87), less than Enveric Biosciences, Inc. (-0.33), less than eFFECTOR Therapeutics, Inc. (-0.00), less than Immix Biopharma, Inc. (-2.39), less than Elevation Oncology, Inc. (-0.78), less than Day One Biopharmaceuticals, Inc. (-17.12), less than Acumen Pharmaceuticals, Inc. (-2.73), less than VectivBio Holding AG (-7.94),
Company | PE Ratio | Market cap |
---|---|---|
-0.70 | $47.68M | |
-1.05 | $33.39M | |
-30.90 | $1.20B | |
-2.14 | $31.74M | |
-0.14 | $4.55M | |
-0.03 | $2.55M | |
-0.93 | $22.42M | |
-0.52 | $91.71M | |
6.04 | $89.59M | |
-16.88 | $616.59M | |
-3.09 | $277.29M | |
-5.51 | $599.50M | |
-2.39 | $140.43M | |
-10.87 | $278.69M | |
-0.33 | $4.14M | |
-0.00 | $1.88K | |
-2.39 | $43.37M | |
-0.78 | $30.89M | |
-17.12 | $1.49B | |
-2.73 | $177.24M | |
-7.94 | $1.06B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rigel Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Rigel Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Rigel Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Rigel Pharmaceuticals, Inc. (RIGL)?
What is the highest PE Ratio for Rigel Pharmaceuticals, Inc. (RIGL)?
What is the 3-year average PE Ratio for Rigel Pharmaceuticals, Inc. (RIGL)?
What is the 5-year average PE Ratio for Rigel Pharmaceuticals, Inc. (RIGL)?
How does the current PE Ratio for Rigel Pharmaceuticals, Inc. (RIGL) compare to its historical average?